top of page
END-TO-END AMSC DELIVERY
The Revalyxis™ Platform
Platform, not pipeline.
Revalyxis™ is a licensable technology - one investment enables unlimited parallel pharmaceutical partnerships. Revenue compounds across channels without proportional cost growth.
01
SOURCE
Post-birth amniotic fluid, ethically collected from consented donors - no fetal tissue, no invasive procedures.
02
ISOLATE
Proprietary cell separation workflows producing natal, biologically early-stage MSCs.
03
EXPAND
Scalable culture protocol for AMSC proliferation, potency, and yield - with consistent donor-to-donor quality.
04
DELIVER
GMP-compatible formulation and cryopreservation supplied to pharma and biotech partners.
bottom of page